Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Viibryd (Vilazodone HCL) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2012

Summary View

 

(Serotonin Toxicity associated with co-administration with Linezolid and Methylene Blue)
 

CONTRAINDICATIONS

Serotonin Syndrome and MAOIs:
  • Starting Viibryd in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome
 

WARNINGS AND PRECAUTIONS

Serotonin Syndrome
  • The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Viibryd, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, Fentanyl, Lithium, Tramadol, Tryptophan, Buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)…

 

-
-